Methyldopa injection contraindications: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
{{CMG}}; {{AE}} {{AK}} | {{CMG}}; {{AE}} {{AK}} | ||
CONTRAINDICATIONS | ==CONTRAINDICATIONS== | ||
Methyldopate hydrochloride is contraindicated in patients: | Methyldopate hydrochloride is contraindicated in patients: | ||
| Line 10: | Line 10: | ||
- with liver disorders previously associated with methyldopa therapy (see [[Methyldopa injection warnings|WARNINGS]]). | - with liver disorders previously associated with methyldopa therapy (see [[Methyldopa injection warnings|WARNINGS]]). | ||
- with hypersensitivity to any component of this product, including [[sulfites ]](see [[Methyldopa injection warnings|WARNINGS]]). | - with hypersensitivity to any component of this product, including [[sulfites ]](see [[Methyldopa injection warnings|WARNINGS]]). | ||
- on therapy with [[monoamine oxidase]] (MAO) inhibitors.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = METHYLDOPATE HYDROCHLORIDE INJECTION, SOLUTION [AMERICAN REGENT, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f5f25053-a9f3-48b9-a412-078f5ee942fd | publisher = | date = | accessdate = 10 March 2014 }}</ref> | - on therapy with [[monoamine oxidase]] (MAO) inhibitors.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = METHYLDOPATE HYDROCHLORIDE INJECTION, SOLUTION [AMERICAN REGENT, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=f5f25053-a9f3-48b9-a412-078f5ee942fd | publisher = | date = | accessdate = 10 March 2014 }}</ref> | ||
Revision as of 16:35, 10 March 2014
| Methyldopa |
|---|
| Methyldopa tablet® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings |
| Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| How Supplied/Storage and Handling |
| Labels and Packages |
| Methyldopa injection® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings |
| Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| How Supplied/Storage and Handling |
| Labels and Packages |
| Clinical Trials on Methyldopa |
| ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]
CONTRAINDICATIONS
Methyldopate hydrochloride is contraindicated in patients:
- with active hepatic disease, such as acute hepatitis and active cirrhosis.
- with liver disorders previously associated with methyldopa therapy (see WARNINGS).
- with hypersensitivity to any component of this product, including sulfites (see WARNINGS).
- on therapy with monoamine oxidase (MAO) inhibitors.[1]
References
- ↑ "METHYLDOPATE HYDROCHLORIDE INJECTION, SOLUTION [AMERICAN REGENT, INC.]". Retrieved 10 March 2014.